Literature DB >> 18343727

Treatment of chronic femoral osteomyelitis with platelet-rich plasma (PRP): a case report.

Ting Yuan1, Changqing Zhang, Bingfang Zeng.   

Abstract

Chronic osteomyelitis is a serious problem in developing countries. A lot of patients with chronic osteomyelitis have to be treated for a very long period and get several operations including complete debridement, antibiotic bead implant, bone grafts, etc. However, traditional methods seem to be ineffective in some patients, who always have a high incidence of recurrence. We report a case of chronic osteomyelitis in bilateral femurs, which has been treated with long time antibiotic therapy, about twenty debridements, yet the sinus remained unhealed for over four years. At the end of this period, we used PRP to treat the unhealed sinus and obtained good results. Though the mechanism by which PRP treats chronic osteomyelitis is now unclear, the results encourage study further.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343727     DOI: 10.1016/j.transci.2008.01.006

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  11 in total

1.  Chronic calcaneal osteomyelitis associated with soft-tissue defect could be successfully treated with platelet-rich plasma: a case report.

Authors:  Hsin-Fu Wang; You-Shui Gao; Ting Yuan; Xiao-Wei Yu; Chang-Qing Zhang
Journal:  Int Wound J       Date:  2012-02-24       Impact factor: 3.315

Review 2.  Platelet-Rich Plasma for the Treatment of Tissue Infection: Preparation and Clinical Evaluation.

Authors:  Wenhai Zhang; Yue Guo; Mitchell Kuss; Wen Shi; Amy L Aldrich; Jason Untrauer; Tammy Kielian; Bin Duan
Journal:  Tissue Eng Part B Rev       Date:  2019-05-15       Impact factor: 6.389

3.  Unique antimicrobial effects of platelet-rich plasma and its efficacy as a prophylaxis to prevent implant-associated spinal infection.

Authors:  Hongshuai Li; Therwa Hamza; John E Tidwell; Nina Clovis; Bingyun Li
Journal:  Adv Healthc Mater       Date:  2013-02-27       Impact factor: 9.933

Review 4.  Targeting the host hemostatic system function in bacterial infection for antimicrobial therapies.

Authors:  Yuanxi Xu; Haiqing Yu; Hongmin Sun
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

5.  Temporal Bacteriostatic Effect and Growth Factor Loss in Equine Platelet Components and Plasma Cultured with Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus: A Comparative In Vitro Study.

Authors:  Catalina López; María E Alvarez; Jorge U Carmona
Journal:  Vet Med Int       Date:  2014-11-24

6.  Plasma components and platelet activation are essential for the antimicrobial properties of autologous platelet-rich plasma: an in vitro study.

Authors:  Lorenzo Drago; Monica Bortolin; Christian Vassena; Carlo L Romanò; Silvio Taschieri; Massimo Del Fabbro
Journal:  PLoS One       Date:  2014-09-18       Impact factor: 3.240

7.  Exosomes derived from platelet-rich plasma promote the re-epithelization of chronic cutaneous wounds via activation of YAP in a diabetic rat model.

Authors:  Shang-Chun Guo; Shi-Cong Tao; Wen-Jing Yin; Xin Qi; Ting Yuan; Chang-Qing Zhang
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

8.  Exosomes derived from human platelet-rich plasma prevent apoptosis induced by glucocorticoid-associated endoplasmic reticulum stress in rat osteonecrosis of the femoral head via the Akt/Bad/Bcl-2 signal pathway.

Authors:  Shi-Cong Tao; Ting Yuan; Bi-Yu Rui; Zhen-Zhong Zhu; Shang-Chun Guo; Chang-Qing Zhang
Journal:  Theranostics       Date:  2017-01-15       Impact factor: 11.556

Review 9.  An overview of platelet products (PRP, PRGF, PRF, etc.) in the Iranian studies.

Authors:  Seyed Ahmad Raeissadat; Marzieh Babaee; Seyed Mansour Rayegani; Zahra Hashemi; Amir Ali Hamidieh; Parviz Mojgani; Hossein Fouladi Vanda
Journal:  Future Sci OA       Date:  2017-07-28

10.  Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity.

Authors:  Lorenzo Drago; Monica Bortolin; Christian Vassena; Silvio Taschieri; Massimo Del Fabbro
Journal:  BMC Microbiol       Date:  2013-02-25       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.